{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:09:07Z","timestamp":1792292947680,"version":"4.4.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.phrs.2019.104512","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T02:47:43Z","timestamp":1573526863000},"page":"104512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo"],"prefix":"10.1016","volume":"151","author":[{"given":"Zhuojun","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxia","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.phrs.2019.104512_bib0005","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1073\/pnas.1308374111","article-title":"ROR1 can interact with TCL1 and enhance leukemogenesis in Emu-TCL1 transgenic mice","volume":"111","author":"Widhopf","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"6","key":"10.1016\/j.phrs.2019.104512_bib0010","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/leu.2011.362","article-title":"Monoclonal antibod ies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells","volume":"26","author":"Daneshmanesh","year":"2012","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.phrs.2019.104512_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061167","article-title":"Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells","volume":"8","author":"Hojjat-Farsangi","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.phrs.2019.104512_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021018","article-title":"Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies","volume":"6","author":"Yang","year":"2011","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.phrs.2019.104512_bib0025","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1073\/pnas.0712148105","article-title":"Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a","volume":"105","author":"Fukuda","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"2","key":"10.1016\/j.phrs.2019.104512_bib0030","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1172\/JCI83535","article-title":"Wnt5a induces ROR1\/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation","volume":"126","author":"Yu","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.phrs.2019.104512_bib0035","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1365-2141.2010.08362.x","article-title":"Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells","volume":"151","author":"Choudhury","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.phrs.2019.104512_bib0040","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2017.132","article-title":"Wnt5a induces ROR1 to associate with 14-3-3zeta for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells","author":"Yu","year":"2017","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.phrs.2019.104512_bib0045","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood-2016-04-712562","article-title":"High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia","volume":"128","author":"Cui","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.phrs.2019.104512_bib0050","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2887","article-title":"Targeting the dynamic HSP90 complex in cancer","volume":"10","author":"Trepel","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.phrs.2019.104512_bib0055","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1182\/blood-2005-03-1099","article-title":"ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia","volume":"106","author":"Castro","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.phrs.2019.104512_bib0060","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2010-01-263756","article-title":"17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition","volume":"116","author":"Hertlein","year":"2010","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.phrs.2019.104512_bib0065","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2013-01-479972","article-title":"Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies","volume":"122","author":"Nayar","year":"2013","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.phrs.2019.104512_bib0070","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1182\/blood-2015-03-635821","article-title":"Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias","volume":"126","author":"Kucine","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.phrs.2019.104512_bib0075","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1182\/blood-2016-06-721423","article-title":"HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling","volume":"129","author":"Walter","year":"2017","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.phrs.2019.104512_bib0080","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1182\/blood-2016-08-735886","article-title":"Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice","volume":"129","author":"Huang","year":"2017","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.phrs.2019.104512_bib0085","first-page":"1278","article-title":"Ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.phrs.2019.104512_bib0090","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.phrs.2019.104512_bib0095","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.phrs.2019.104512_bib0100","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.phrs.2019.104512_bib0105","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/leu.2016.368","article-title":"Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib","volume":"31","author":"Yu","year":"2017","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.phrs.2019.104512_bib0110","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1182\/blood-2016-04-711176","article-title":"HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma","volume":"128","author":"Jacobson","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.phrs.2019.104512_bib0115","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1038\/leu.2017.132","article-title":"Wnt5a induces ROR1 to associate with 14-3-3zeta for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells","volume":"31","author":"Yu","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.phrs.2019.104512_bib0120","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1182\/blood-2012-09-457374","article-title":"Heat shock protein 70 regulates Tcl1 expression in leukemia and lymphomas","volume":"121","author":"Gaudio","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.phrs.2019.104512_bib0125","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.stem.2018.12.013","article-title":"Cholesterol metabolism is a druggable Axis that independently regulates tau and amyloid-beta in iPSC-Derived alzheimer\u2019s disease neurons","volume":"24","author":"van der Kant","year":"2019","journal-title":"Cell Stem Cell"},{"issue":"20","key":"10.1016\/j.phrs.2019.104512_bib0130","doi-asserted-by":"crossref","first-page":"14361","DOI":"10.1074\/jbc.M512613200","article-title":"Hsp90 recognizes a common surface on client kinases","volume":"281","author":"Citri","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"37","key":"10.1016\/j.phrs.2019.104512_bib0135","doi-asserted-by":"crossref","first-page":"26879","DOI":"10.1074\/jbc.M113.492280","article-title":"Destabilization of the epidermal growth factor receptor (EGFR) by a peptide that inhibits EGFR binding to heat shock protein 90 and receptor dimerization","volume":"288","author":"Ahsan","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.phrs.2019.104512_bib0140","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.4049\/jimmunol.1600915","article-title":"Functional differences between IgM and IgD signaling in chronic lymphocytic leukemia","volume":"197","author":"Ten Hacken","year":"2016","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104512_bib0145","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1182\/blood-2009-03-212837","article-title":"B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406","volume":"114","author":"Quiroga","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.phrs.2019.104512_bib0150","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.phrs.2019.104512_bib0155","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.ajpath.2012.08.024","article-title":"The onco-embryonic antigen ROR1 is expressed by a variety of human cancers","volume":"181","author":"Zhang","year":"2012","journal-title":"Am. J. Pathol."},{"issue":"12","key":"10.1016\/j.phrs.2019.104512_bib0160","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1172\/JCI80714","article-title":"Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma","volume":"125","author":"Goldstein","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.phrs.2019.104512_bib0165","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrm2918","article-title":"HSP90 at the hub of protein homeostasis: emerging mechanistic insights","volume":"11","author":"Taipale","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"16","key":"10.1016\/j.phrs.2019.104512_bib0170","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1182\/blood-2011-06-338855","article-title":"B-cell receptor signaling in chronic lymphocytic leukemia","volume":"118","author":"Stevenson","year":"2011","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.phrs.2019.104512_bib0175","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2019.104512_bib0180","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.phrs.2019.104512_bib0185","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1182\/blood-2014-12-619163","article-title":"Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy","volume":"125","author":"de Rooij","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.phrs.2019.104512_bib0190","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1158\/1078-0432.CCR-15-1304","article-title":"Interactions between ibrutinib and Anti-CD20 antibodies: competing effects on the outcome of combination therapy","volume":"22","author":"Skarzynski","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.phrs.2019.104512_bib0195","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1080\/10428194.2017.1312387","article-title":"The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia","volume":"58","author":"Aw","year":"2017","journal-title":"Leuk. Lymphoma"},{"issue":"11","key":"10.1016\/j.phrs.2019.104512_bib0200","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1158\/1541-7786.MCR-15-0234","article-title":"Maximizing the therapeutic potential of HSP90 inhibitors","volume":"13","author":"Butler","year":"2015","journal-title":"Mol. Cancer Res."},{"issue":"7","key":"10.1016\/j.phrs.2019.104512_bib0205","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/nrc1887","article-title":"Drug interactions in cancer therapy","volume":"6","author":"Scripture","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2019.104512_bib0210","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J. Clin. Oncol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819321012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819321012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:08:15Z","timestamp":1760911695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661819321012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":42,"alternative-id":["S1043661819321012"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104512","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104512","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104512"}}